The identification by researchers at Daichii Pharmaceutical Co. of SADS, a small protein that drives the Fas apoptosis pathway, helps to define methods that lymphocytes use to kill tumor cells. As a positive regulator of Fas-induced apoptosis, restoring SADS activity in tumors with low levels of the protein or inducing overexpression of SADS may provide a broadly applicable method of treating cancers by increasing lymphocyte efficiency at killing tumor cells.

Daichii scientists last week described in Nature Medicine the identification of SADS (small accelerator of death-signaling), which is expressed in lung, liver, small intestine, lung and brain tissue. Fas is a transmembrane